antipyrine has been researched along with Heart Failure in 8 studies
Antipyrine: An analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29)
antipyrine : A pyrazolone derivative that is 1,2-dihydropyrazol-3-one substituted with methyl groups at N-1 and C-5 and with a phenyl group at N-2.
Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Edaravone suppressed plasma MCP-1, improved left ventricular ejection fraction, and reduced rehospitalization due to heart failure." | 9.14 | Effect of edaravone on plasma monocyte chemoattractant protein-1 levels in patients with acute myocardial infarction. ( Chitose, T; Fukuda, M; Kaikita, K; Nagata, T; Nagayoshi, Y; Nakamura, Y; Nako, H; Ogawa, H; Ogura, Y; Ohba, K; Shimomura, H; Soejima, H; Sugiyama, S; Tsujita, K; Yamada, Y; Yamaguchi, M; Yamashita, T, 2009) |
| "Edaravone suppressed plasma MCP-1, improved left ventricular ejection fraction, and reduced rehospitalization due to heart failure." | 5.14 | Effect of edaravone on plasma monocyte chemoattractant protein-1 levels in patients with acute myocardial infarction. ( Chitose, T; Fukuda, M; Kaikita, K; Nagata, T; Nagayoshi, Y; Nakamura, Y; Nako, H; Ogawa, H; Ogura, Y; Ohba, K; Shimomura, H; Soejima, H; Sugiyama, S; Tsujita, K; Yamada, Y; Yamaguchi, M; Yamashita, T, 2009) |
| "During the development of heart failure, edaravone ameliorated the defective interdomain interaction of the RyR2." | 3.73 | Correction of defective interdomain interaction within ryanodine receptor by antioxidant is a new therapeutic strategy against heart failure. ( Doi, M; Ikeda, Y; Ikemoto, N; Kobayashi, S; Matsuzaki, M; Mochizuki, M; Noma, T; Oda, T; Ohkusa, T; Okuda, S; Tateishi, H; Tokuhisa, T; Yamamoto, T; Yano, M, 2005) |
| "Antipyrine was used to assess the status of drug metabolism in ten female patients with congestive cardiac failure." | 3.66 | Alteration of hepatic drug metabolism in female patients with congestive cardiac failure. ( Anand, IS; Madappa, C; Nair, CR; Rissam, HS; Wahi, PL, 1983) |
| " Hepatic pharmacokinetic modelling was performed with a two-phase physiologically-based organ pharmacokinetic model with the vascular space and dispersion evaluated with the MID technique." | 1.38 | Hepatocellular necrosis, fibrosis and microsomal activity determine the hepatic pharmacokinetics of basic drugs in right-heart-failure-induced liver damage. ( Crawford, DH; Fletcher, LM; Li, P; Roberts, MS; Robertson, TA; Weiss, M; Zhang, Q, 2012) |
| "In six patients without cardiac failure the plasma concentrations of lignocaine rose progressively during the infusion and the mean lignocaine half life was 4." | 1.26 | Impaired Lignocaine metabolism in patients with myocardial infarction and cardiac failure. ( Adjepon-Yamoah, KK; Prescott, LF; Talbot, RG, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (62.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nakamura, Y | 1 |
| Yamada, Y | 1 |
| Shimomura, H | 1 |
| Nagayoshi, Y | 1 |
| Tsujita, K | 1 |
| Yamashita, T | 1 |
| Fukuda, M | 1 |
| Ohba, K | 1 |
| Nako, H | 1 |
| Ogura, Y | 1 |
| Chitose, T | 1 |
| Yamaguchi, M | 1 |
| Nagata, T | 1 |
| Soejima, H | 1 |
| Kaikita, K | 1 |
| Sugiyama, S | 1 |
| Ogawa, H | 1 |
| Li, P | 1 |
| Robertson, TA | 1 |
| Zhang, Q | 1 |
| Fletcher, LM | 1 |
| Crawford, DH | 1 |
| Weiss, M | 1 |
| Roberts, MS | 1 |
| Yano, M | 1 |
| Okuda, S | 1 |
| Oda, T | 1 |
| Tokuhisa, T | 1 |
| Tateishi, H | 1 |
| Mochizuki, M | 1 |
| Noma, T | 1 |
| Doi, M | 1 |
| Kobayashi, S | 1 |
| Yamamoto, T | 1 |
| Ikeda, Y | 1 |
| Ohkusa, T | 1 |
| Ikemoto, N | 1 |
| Matsuzaki, M | 1 |
| Rissam, HS | 1 |
| Nair, CR | 1 |
| Anand, IS | 1 |
| Madappa, C | 1 |
| Wahi, PL | 1 |
| Masson, JP | 1 |
| Bass, O | 1 |
| Baur, HR | 1 |
| Ohnhaus, EE | 1 |
| Adamska-Dyniewska, H | 1 |
| Prescott, LF | 1 |
| Adjepon-Yamoah, KK | 1 |
| Talbot, RG | 1 |
| Sycheva, IM | 1 |
| Vinogradov, AV | 1 |
| Kuz'mina, AE | 1 |
| Kiseleva, ZM | 1 |
1 trial available for antipyrine and Heart Failure
| Article | Year |
|---|---|
Effect of edaravone on plasma monocyte chemoattractant protein-1 levels in patients with acute myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Antipyrine; Biomarkers; Chemokine CCL2; Edaravone; Female; Fre | 2009 |
7 other studies available for antipyrine and Heart Failure
| Article | Year |
|---|---|
Hepatocellular necrosis, fibrosis and microsomal activity determine the hepatic pharmacokinetics of basic drugs in right-heart-failure-induced liver damage.
Topics: Adrenergic Antagonists; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti | 2012 |
Correction of defective interdomain interaction within ryanodine receptor by antioxidant is a new therapeutic strategy against heart failure.
Topics: Animals; Antioxidants; Antipyrine; Calcium; Cardiac Pacing, Artificial; Dogs; Edaravone; Heart Failu | 2005 |
Alteration of hepatic drug metabolism in female patients with congestive cardiac failure.
Topics: Adolescent; Adult; Alanine Transaminase; Alkaline Phosphatase; Antipyrine; Bilirubin; Blood Proteins | 1983 |
[The pharmacokinetics of digoxin during chronic spironolacton treatment (author's transl)].
Topics: Adult; Aged; Antipyrine; Digoxin; Feces; Female; Half-Life; Heart Failure; Humans; Kinetics; Male; M | 1978 |
[Liver capacity in the biotransformation of drugs in patients with chronic circulatory failure (kinetics of antipyrine and indocyanine green)].
Topics: Antipyrine; Biotransformation; Heart Failure; Humans; Indocyanine Green; Kinetics; Liver | 1978 |
Impaired Lignocaine metabolism in patients with myocardial infarction and cardiac failure.
Topics: Adult; Aged; Antipyrine; Half-Life; Heart Failure; Humans; Lidocaine; Male; Middle Aged; Myocardial | 1976 |
[Distribution of fluid between the cells and the extracellular media and mineralocorticoid function of the adrenal glands in cardiac insufficiency].
Topics: Adrenal Glands; Adult; Aldosterone; Antipyrine; Body Fluids; Chromatography, Paper; Coronary Disease | 1969 |